NCT06263348CompletedPhase 4
A Post-Marketing Safety Study of Dorzagliatin in Patients With Type 2 Diabetes
A Multicenter Post-Marketing Observational Study to Evaluate the Long-Term Safety of Dorzagliatin in Patients With Type 2 Diabetes Mellitus
Source: ClinicalTrials.gov · Last updated 10 Jul 2026
Brief summary (registry, in English)
The primary objective of this study is to evaluate the long-term safety of Dorzagliatin in a larger population of type 2 diabetes mellitus patients by collecting the post-marketing clinical safety data of Dorzagliatin.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 2024 (actual)
- First submitted
- 5 Feb 2024
- Start date
- 17 Jan 2024
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Hua Medicine Limited
- Diseases
- Type 2 diabetes
- NCT number
- NCT06263348
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 2024
- From 17 Jan 2024 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Other types of clinically diagnosed diabetes, such as type 1 diabetes or other special types of diabetes;
- Patients who, in the opinion of the investigator, are at risk of allergy or intolerance to any component of Dorzagliatin;
Other
- \-
- Patients will not be eligible if they meet any of the following criteria:
- Patients who, in the judgment of the investigator, cannot complete or are not suitable for this study.
Who the study is looking for
- \-
- Patients must meet all of the following inclusion criteria to be eligible for this study:
- Male or female ≥ 18 years of age at the time of signing the informed consent form;
- Patients with type 2 diabetes mellitus diagnosed at screening;
- Patients who have been prescribed Dorzagliatin according to the package insert and physician's judgment (the prescription should be made before enrolling the patient in this study and is independent of the enrollment decision);
- Willingness to participate in the study and sign written informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| China-Japan Friendship Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.